| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.2 | 4e-05 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.14 | 8e-05 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.19 | 0.0003 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.002 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |